Atomistic Insights Joins HealthWildcatters to Advance Physics-Guided AI for Drug Discovery

(Dallas, Texas) – September 10, 2026 — Atomistic Insights, a biotechnology company developing physics-guided artificial intelligence for protein dynamics and drug discovery, has been selected to join the 14th cohort of the Health Wildcatters Accelerator, a nationally recognized healthcare accelerator and early-stage investment fund based at Pegasus Park in Dallas.

Atomistic Insights is developing technology designed to help drug discovery teams better understand how proteins move, interact, and reveal potential therapeutic opportunities. Its proprietary DeepPath platform identifies biologically relevant protein conformations and previously hidden drug-binding opportunities in hours rather than months, enabling discovery teams to uncover new binding pockets, prioritize compounds, and accelerate therapeutic development.

“Joining Health Wildcatters represents an exciting opportunity for Atomistic Insights as we continue advancing DeepPath and expanding its applications in drug discovery,” said Dr. Katie Kuo, CEO and co-founder.

Atomistic Insights’ participation in Health Wildcatters marks an important step in the company’s efforts to accelerate the development and commercialization of its technology while building relationships across the healthcare, biotechnology, pharmaceutical, and investment communities.

“We are excited to welcome Atomistic Insights to our 14th accelerator cohort,” said Dr. Hubert Zajicek, CEO and co-founder of Health Wildcatters. “Their approach brings together physics and artificial intelligence to address an important challenge in drug discovery. We look forward to supporting the team as they advance their technology and explore opportunities to accelerate therapeutic development.”

As part of the accelerator, Atomistic Insights will participate in Health Wildcatters’ 12-week program, gaining access to experienced mentors, healthcare executives, investors, strategic partners, and educational programming designed to support commercialization, fundraising, and growth. The program will culminate with Health Wildcatters’ annual Pitch Day in November 2026.

About Health Wildcatters

Health Wildcatters is a Dallas-based seed accelerator and investment firm, consistently recognized among the nation’s top healthcare accelerators. Over the past thirteen years, it has built a portfolio of 127 companies driving innovation in digital health, medical devices, diagnostics, and biotech. Collectively, these startups have raised more than $350 million to advance healthcare solutions worldwide. Through its flagship accelerator program, Health Wildcatters provides early-stage capital, expert mentorship, and access to a robust network of investors and industry leaders. To learn more, visit www.healthwildcatters.com.